BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The current clinical management and guidelines of CML treatment require the close molecular monitoring of BCR::ABL1 expression for both treatment effectiveness evaluation guiding to targeted therapy and TKIs discontinuation protocol.